Puretech Health Plc - Adr (PRTC)

$20.55

+0.61

(+3.06%)▲

Live

Performance

  • $19.46
    $20.80
    $20.55
    downward going graph

    5.3%

    Downside

    Day's Volatility :6.44%

    Upside

    1.2%

    downward going graph
  • $17.08
    $34.00
    $20.55
    downward going graph

    16.89%

    Downside

    52 Weeks Volatility :49.76%

    Upside

    39.56%

    downward going graph

Returns

PeriodPuretech Health Plc - AdrSector (Health Care)Index (Russel 2000)
3 Months
-8.95%
3.6%
0.0%
6 Months
-27.44%
10.2%
0.0%
1 Year
-0.3%
19.6%
0.0%
3 Years
-60.9%
16.8%
-23.0%

Highlights

Market Capitalization
465.0M
Book Value
$1.32
Earnings Per Share (EPS)
-3.0
Wall Street Target Price
52.75
Profit Margin
0.0%
Operating Margin TTM
-23054.86%
Return On Assets TTM
-13.39%
Return On Equity TTM
-22.07%
Revenue TTM
468.0K
Revenue Per Share TTM
0.02
Quarterly Revenue Growth YOY
-90.9%
Gross Profit TTM
17.4M
EBITDA
-134.7M
Diluted Eps TTM
-3.0
Quarterly Earnings Growth YOY
0.62
EPS Estimate Current Year
-0.4
EPS Estimate Next Year
-0.5
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    83%Buy
    16%Hold
    0
    0%Sell
Based on 6 Wall street analysts offering stock ratings for Puretech Health Plc - Adr(by analysts ranked 0 to 5 stars)
Based on 6 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
5
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 156.69%

Current $20.55
Target $52.75

Company Financials

FY18Y/Y Change
Revenue
16.4M
↑ 2418.62%
Net Income
-43.7M
↓ 241.42%
Net Profit Margin
-266.65%
↓ 5015.73%
FY19Y/Y Change
Revenue
8.7M
↓ 46.93%
Net Income
421.1M
↓ 1064.73%
Net Profit Margin
4.8K%
↑ 5114.07%
FY20Y/Y Change
Revenue
8.3M
↓ 3.99%
Net Income
4.6M
↓ 98.92%
Net Profit Margin
54.77%
↓ 4792.65%
FY21Y/Y Change
Revenue
10.0M
↑ 19.64%
Net Income
-62.7M
↓ 1472.79%
Net Profit Margin
-628.41%
↓ 683.18%
FY22Y/Y Change
Revenue
2.1M
↓ 79.06%
Net Income
-37.1M
↓ 40.9%
Net Profit Margin
-1.8K%
↓ 1144.99%
FY23Y/Y Change
Revenue
3.3M
↑ 59.33%
Net Income
-65.7M
↑ 77.25%
Net Profit Margin
-2.0K%
↓ 199.48%
Q1 FY23Q/Q Change
Revenue
1.6M
-
Net Income
-12.5M
-
Net Profit Margin
-793.78%
-
Q2 FY23Q/Q Change
Revenue
3.2M
↑ 100.0%
Net Income
-25.0M
↑ 100.01%
Net Profit Margin
-793.81%
↓ 0.03%
Q3 FY23Q/Q Change
Revenue
90.0K
↓ 97.14%
Net Income
-20.3M
↓ 18.63%
Net Profit Margin
-22.6K%
↓ 21813.41%
Q1 FY24Q/Q Change
Revenue
144.0K
↑ 60.0%
Net Income
-20.9M
↑ 2.65%
Net Profit Margin
-14.5K%
↑ 8102.71%
Q2 FY24Q/Q Change
Revenue
144.0K
↑ 0.0%
Net Income
-20.9M
↑ 0.0%
Net Profit Margin
-14.5K%
↑ 0.0%
FY18Y/Y Change
Total Assets
441.8M
↑ 29.99%
Total Liabilities
274.8M
↓ 0.38%
FY19Y/Y Change
Total Assets
941.2M
↑ 113.05%
Total Liabilities
290.8M
↑ 5.82%
FY20Y/Y Change
Total Assets
990.0M
↑ 5.19%
Total Liabilities
336.5M
↑ 15.71%
FY21Y/Y Change
Total Assets
946.0M
↓ 4.44%
Total Liabilities
361.9M
↑ 7.55%
FY22Y/Y Change
Total Assets
702.6M
↓ 25.72%
Total Liabilities
155.1M
↓ 57.15%
FY23Y/Y Change
Total Assets
694.0M
↓ 1.23%
Total Liabilities
125.6M
↓ 19.01%
Q1 FY23Q/Q Change
Total Assets
693.6M
↓ 1.29%
Total Liabilities
184.7M
↑ 19.09%
Q2 FY23Q/Q Change
Total Assets
693.6M
↑ 0.0%
Total Liabilities
184.7M
↑ 0.0%
Q3 FY23Q/Q Change
Total Assets
694.0M
↑ 0.06%
Total Liabilities
235.7M
↑ 27.66%
Q4 FY23Q/Q Change
Total Assets
694.0M
↑ 0.0%
Total Liabilities
235.7M
↑ 0.0%
Q1 FY24Q/Q Change
Total Assets
580.0M
↓ 16.43%
Total Liabilities
273.7M
↑ 16.12%
Q2 FY24Q/Q Change
Total Assets
580.0M
↑ 0.0%
Total Liabilities
273.7M
↑ 0.0%
FY18Y/Y Change
Operating Cash Flow
-72.8M
↓ 17.92%
Investing Cash Flow
-39.6M
↓ 147.38%
Financing Cash Flow
156.9M
↑ 967.55%
FY19Y/Y Change
Operating Cash Flow
-98.2M
↑ 34.84%
Investing Cash Flow
63.7M
↓ 260.57%
Financing Cash Flow
49.9M
↓ 68.19%
FY20Y/Y Change
Operating Cash Flow
-131.8M
↑ 34.3%
Investing Cash Flow
364.5M
↑ 472.55%
Financing Cash Flow
38.9M
↓ 22.12%
FY21Y/Y Change
Operating Cash Flow
-158.3M
↑ 20.06%
Investing Cash Flow
197.4M
↓ 45.85%
Financing Cash Flow
22.7M
↓ 41.53%
Q4 FY22Q/Q Change
Operating Cash Flow
-32.6M
↓ 28.85%
Investing Cash Flow
86.9M
↑ 0.0%
Financing Cash Flow
45.9M
↓ 480.34%
Q1 FY23Q/Q Change
Operating Cash Flow
-32.6M
↑ 0.0%
Investing Cash Flow
86.9M
↑ 0.0%
Financing Cash Flow
45.9M
↑ 0.0%
Q2 FY23Q/Q Change
Operating Cash Flow
-65.1M
↑ 100.0%
Investing Cash Flow
86.9M
↑ 0.0%
Financing Cash Flow
91.9M
↑ 100.0%

Technicals Summary

Sell

Neutral

Buy

Puretech Health Plc - Adr is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Puretech Health Plc - Adr
Puretech Health Plc - Adr
0.73%
-27.44%
-0.3%
-60.9%
-59.26%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-9.28%
10.06%
24.53%
74.0%
232.45%
Novo Nordisk A/s
Novo Nordisk A/s
-4.54%
-5.72%
21.59%
126.2%
349.01%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
8.87%
102.98%
82.67%
44.83%
241.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
5.0%
20.77%
31.37%
158.16%
163.17%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Puretech Health Plc - Adr
Puretech Health Plc - Adr
NA
NA
NA
-0.4
-0.22
-0.13
NA
1.32
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.41
26.41
1.37
44.9
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.21
40.21
1.81
3.36
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.42
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.59
0.18
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Puretech Health Plc - Adr
Puretech Health Plc - Adr
Buy
$465.0M
-59.26%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$110.0B
232.45%
26.41
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$529.8B
349.01%
40.21
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$38.1B
241.09%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.7B
163.17%
32.84
-4.74%

Insights on Puretech Health Plc - Adr

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 90.0K → 144.0K (in $), with an average increase of 18.8% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -20.34M → -20.88M (in $), with an average decrease of 1.3% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 83.2%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 105.7%

Institutional Holdings

  • Pentwater Capital Management LP

    0.07%

  • Morgan Stanley - Brokerage Accounts

    0.01%

Company Information

PureTech Health is a biotechnology company which develops medicines to combat serious diseases.

Organization
Puretech Health Plc - Adr
Employees
90
CEO
Dr. Bharatt M. Chowrira J.D., Ph.D.
Industry
Health Technology

Discover More

FAQs